Eris Lifesciences Ltd.

ERIS

₹1735.8

-2.49% (-44.4)

Market Cap

₹23,634 Cr.

P/E

67.17

Key Ratios

Edit Ratio's

Market cap

23,634 Cr

67.17

Prom Holding

54.85 %

ROE (%)

15.16

ROCE (%)

12.26

Div Yield (%)

0.42

Sales

2,893 Cr

OPM (%)

35.15 %

Debt to Equity

1.06

Edit Ratio's

About

Eris Lifesciences Limited, founded in 2007 by Amit Bakshi, is a rapidly growing company in the… Read more

Low

987

52W Range

High

1910

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Promoter Holding

Promoter has not sold any shares in the last 90 days
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
Sales Growth

Sales of the company has grown at a good pace
Balance Sheet Strength

Balance sheet of the company is strong. it shouldnt have solvency or liquidity issues
Capex vs ROCE

Company has made significant capex which might be affecting its roce
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
ROE

Roe has decreased vs 10 year trend
Share price

Share price has increased over last 10 years but more due to rerating
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Market Share

3.77 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.03 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.10 %

(as of Nov 21)

Historic

Blood Related - Market Share

1.99 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

10 %

(as of Mar 24)

Source/Historic

Cyblex - Market Share

0.04 %

(as of Nov 21)

Historic

Dermatology - Market Share

9.10 %

(as of Mar 19)

Source/Historic

Desval - Market Share

0.10 %

(as of Nov 21)

Historic

Endocrinology - Market Share

4 %

(as of Mar 24)

Source/Historic

Eritel - Market Share

0.35 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

35 %

(as of Mar 24)

Source/Historic

Ginkocer - Market Share

6 %

(as of Mar 24)

Source/Historic

Glimisave - Market Share

0.70 %

(as of Nov 21)

Historic

Gynecology - Market Share

1.20 %

(as of Mar 19)

Source/Historic

Levroxa - Market Share

9 %

(as of Mar 24)

Source/Historic

Lnbloc - Market Share

8 %

(as of Sep 22)

Source/Historic

Metital - Market Share

1.16 %

(as of Nov 21)

Historic

Neurological - Market Share

9 %

(as of Mar 24)

Source/Historic

Olmin - Market Share

0.08 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

0.42 %

(as of Nov 21)

Historic

Pain - Market Share

7.30 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

2 %

(as of Mar 24)

Source/Historic

Rabonik - Market Share

10 %

(as of Mar 23)

Source/Historic

Raricap - Market Share

5 %

(as of Mar 24)

Source/Historic

Remylin - Market Share

7 %

(as of Mar 24)

Source/Historic

Renerve - Market Share

0.12 %

(as of Nov 21)

Historic

Respiratory - Market Share

4.50 %

(as of Mar 19)

Source/Historic

Selzic - Market Share

16 %

(as of Mar 23)

Source/Historic

Serlift - Market Share

4 %

(as of Mar 24)

Source/Historic

Tayo - Market Share

8 %

(as of Mar 23)

Source/Historic

Tendia - Market Share

2.09 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Therapeutic Area Wise Break-Up - Domestic

Entity Wise Breakup

Location Wise Break-Up

Acute vs Chronic

Operational Metrics

Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

FAQs on Eris Lifesciences Ltd. Business

What does Eris Lifesciences do?

Eris Lifesciences Limited, founded in 2007, is a fast-growing company in the Indian Branded Formulations market, focusing on cardiovascular, anti-diabetes, vitamins, gastroenterology, and gynecology products.

Who are the competitors of Eris Lifesciences?

Eris Lifesciences major competitors are Astrazeneca Pharma I, Pfizer, JB Chem & Pharma, Wockhardt, Gland Pharma, Alembic Pharma, Jubilant Pharmova.
Market Cap of Eris Lifesciences is ₹24,223 Crs.
While the median market cap of its peers are ₹26,472 Crs.

Is Eris Lifesciences financially stable compared to its competitors?

Eris Lifesciences seems to be less financially stable compared to its competitors.
Altman Z score of Eris Lifesciences is 4.44 and is ranked 7 out of its 8 competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release
Investor Presentation	May	Feb Mar Jun Sep Dec	Mar Jun Sep Dec	Feb Mar May Jun Aug Sep Dec	Jan Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Sep
Conference Call		Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Eris Lifesciences Ltd.

View the discussion on ValuePickr

Eris Lifesciences - The Pharma Brand Master - Motilal Oswal

Eris Lifesciences - how valuable is it? - ValuePickr

Execution History of Eris Lifesciences - Harsh Beria

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Eris Lifesciences Ltd.

Eris Lifesciences Ltd.

Key Ratios

About

Timeline

Company Timeline

8 Yes

2 Neutral

7 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Other Income

Pledge

Promoter Holding

Retail Holding

Revenue Recognition

Price & Performance

Working Capital

Debt

Sales Growth

Balance Sheet Strength

Capex vs ROCE

Current vs Historic Valuation

ROE

Share price

Margin Stability

ROCE Strength

Product Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Wise Break-Up - Domestic

UNLOCK PREMIUM

Entity Wise Breakup

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Acute vs Chronic

UNLOCK PREMIUM

What does Eris Lifesciences do?

Who are the competitors of Eris Lifesciences?

Is Eris Lifesciences financially stable compared to its competitors?

SIGN UP FOR FREE